Edwards Lifesciences (EW) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
26 Oct, 2026Executive summary
Annual meeting scheduled for May 11, 2023, at 10:00 a.m. Pacific Time; record date was March 13, 2023.
Voting matters and shareholder proposals
Ballot covers director elections, advisory votes on executive compensation and its frequency, auditor ratification, officer exculpation, and an independent-chair policy proposal.
Board recommends FOR proposals 1, 2, 4, and 5; AGAINST proposal 6; and an annual, one-year frequency for future say-on-pay votes.
Board of directors and corporate governance
Nine director nominees: Kieran T. Gallahue, Leslie S. Heisz, Paul A. LaViolette, Steven R. Loranger, Martha H. Marsh, Michael A. Mussallem, Ramona Sequeira, Nicholas J. Valeriani, and Bernard J. Zovighian.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Edwards Lifesciences
- TAVR and TMTT growth lifted FY26 guidance despite impairment and tax headwinds.EW
Q3 2026 - PROGRESS supports earlier TAVR evaluation in at-risk moderate AS; CLASP IITR showed PASCAL health-status gains.EW
Investor update - Board backs all five proposals, including nine directors and two ESPP share increases.EW
Proxy Filing - Nine directors, executive pay, auditor ratification and ESPP share increases go to a vote.EW
Proxy Filing - Board backs all five proposals; 2025 incentives shift to revenue growth and EPS.EW
Proxy Filing - FY23 sales grew 12%; FY24 guidance points to 8%-10% growth.EW
Q4 2023 - Regulatory changes and innovation drive multi-year growth in structural heart therapies.EW
Deutsche Bank 2026 Healthcare Summit - Q2 sales up 13.6% to $1.74B; guidance raised on strong TAVR/TMTT growth and cash position.EW
Q2 2026 - 2026 outlook: 8%-10% sales growth, $2.80-$2.95 EPS, and major heart therapy innovation.EW
Investor Day 2025